Jean-Jacques Risso Selected Research

Oxygen (Dioxygen)

7/2017	Xenon-helium gas mixture at equimolar concentration of 37.5% protects against oxygen and glucose deprivation-induced injury and inhibits tissue plasminogen activator.
7/2016	Effects of normobaric versus hyperbaric oxygen on cell injury induced by oxygen and glucose deprivation in acute brain slices.
4/2016	Hyperbaric oxygen increases tissue-plasminogen activator-induced thrombolysis in vitro, and reduces ischemic brain damage and edema in rats subjected to thromboembolic brain ischemia.
12/2015	Fluoxetine stimulates anti-inflammatory IL-10 cytokine production and attenuates sensory deficits in a rat model of decompression sickness.
10/2015	Xenon Blocks Neuronal Injury Associated with Decompression.
2/2014	Alteration of striatal dopamine levels under various partial pressure of oxygen in pre-convulsive and convulsive phases in freely-moving rats.
1/2012	Ex vivo and in vivo neuroprotection induced by argon when given after an excitotoxic or ischemic insult.
4/2011	Moderately delayed post-insult treatment with normobaric hyperoxia reduces excitotoxin-induced neuronal degeneration but increases ischemia-induced brain damage.
5/2009	Comparison of nitrogen narcosis and helium pressure effects on striatal amino acids: a microdialysis study in rats.
12/2004	Technical aspects of an impact acceleration traumatic brain injury rat model with potential suitability for both microdialysis and PtiO2 monitoring.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Jacques Risso Research Topics

Disease

10	Decompression Sickness (Bends) 01/2019 - 01/2012
9	Ischemic Stroke 07/2017 - 09/2008
9	Ischemia 07/2016 - 04/2008
7	Brain Ischemia (Cerebral Ischemia) 07/2016 - 04/2008
6	Inert Gas Narcosis (Nitrogen Narcosis) 03/2012 - 05/2003
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 04/2016 - 06/2009
4	Stroke (Strokes) 01/2016 - 04/2010
4	Stupor 01/2014 - 03/2003
3	Wounds and Injuries (Trauma) 01/2018 - 01/2013
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2016 - 04/2010
2	High Pressure Neurological Syndrome (High Pressure Nervous Syndrome) 04/2016 - 02/2009
2	Hypothermia 01/2016 - 06/2009
2	Transient Ischemic Attack 09/2008 - 04/2008
1	Infarction (Infarctions) 07/2016
1	Edema (Dropsy) 04/2016
1	Seizures (Absence Seizure) 02/2014
1	Asphyxia (Suffocation) 01/2013
1	Inflammation (Inflammations) 01/2012
1	Hyperoxia 04/2011
1	Gliosis 02/2010
1	Cicatrix (Scar) 12/2009
1	Status Epilepticus (Complex Partial Status Epilepticus) 06/2009
1	Hypoxia (Hypoxemia) 06/2009
1	Epilepsy (Aura) 02/2009
1	Neuroblastoma 12/2008
1	Amnesia (Dissociative Amnesia) 01/2007
1	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2004
1	Hyperkinesis 05/2003
1	Cognitive Dysfunction 05/2003

Drug/Important Bio-Agent (IBA)

10	Oxygen (Dioxygen)IBA 07/2017 - 12/2004
7	Tissue Plasminogen Activator (Alteplase)FDA Link 07/2016 - 04/2010
7	Neuroprotective AgentsIBA 01/2016 - 04/2008
7	NitrogenIBA 01/2014 - 03/2003
5	XenonIBA 01/2016 - 04/2008
5	ArgonIBA 01/2016 - 03/2003
5	Dopamine (Intropin)FDA LinkGeneric 03/2012 - 05/2003
5	N-Methylaspartate (NMDA)IBA 03/2012 - 04/2008
4	Glucose (Dextrose)FDA LinkGeneric 07/2017 - 04/2011
4	Fluoxetine (Prozac)FDA LinkGeneric 01/2017 - 01/2012
4	Noble Gases (Rare Gases)IBA 01/2016 - 05/2003
4	HeliumIBA 01/2016 - 02/2009
4	Nitrous Oxide (Laughing Gas)IBA 01/2014 - 03/2003
3	Antidepressive Agents (Antidepressants)IBA 01/2016 - 01/2012
3	Glutamic Acid (Glutamate)FDA Link 05/2010 - 05/2009
3	Matrix Metalloproteinases (MMPs)IBA 02/2010 - 12/2008
3	Neurotransmitter Agents (Neurotransmitter)IBA 09/2008 - 05/2003
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2017 - 07/2016
2	Narcotics (Narcotic Analgesics)IBA 04/2016 - 05/2003
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2016 - 01/2013
2	potassium channel protein TREK-1IBA 01/2016 - 04/2012
2	gabazineIBA 03/2012 - 03/2003
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Minocycline (Cyclops)FDA LinkGeneric 01/2019
1	Tirofiban (Aggrastat)FDA Link 01/2018
1	Mitochondrial DNA (mtDNA)IBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 01/2018
1	CytokinesIBA 12/2015
1	Interleukin-10 (Interleukin 10)IBA 12/2015
1	Potassium Channels (Potassium Channel)IBA 04/2012
1	Interleukin-6 (Interleukin 6)IBA 01/2012
1	NeurotoxinsIBA 04/2011
1	CalciumIBA 04/2011
1	Serine Proteases (Serine Protease)IBA 04/2010
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2009
1	Pilocarpine (Ocusert)FDA LinkGeneric 06/2009
1	Anesthetics (Anesthetic Agents)IBA 06/2009
1	Amino Acids FDA Link 05/2009
1	Tissue Inhibitor of Metalloproteinase-1IBA 12/2008
1	Proteins (Proteins, Gene)FDA Link 01/2007
1	General AnestheticsIBA 01/2007
1	Ion Channels (Ion Channel)IBA 01/2007
1	GABA AntagonistsIBA 03/2003
1	gamma-Aminobutyric Acid (GABA)IBA 03/2003
1	Flumazenil (Romazicon)FDA LinkGeneric 03/2003
1	GABA-A Receptors (GABA(A) Receptor)IBA 03/2003
1	2-hydroxysaclofenIBA 03/2003
1	GABA-A Receptor AntagonistsIBA 03/2003
1	GABA-B Receptor AntagonistsIBA 03/2003

Therapy/Procedure

4	Therapeutics 01/2016 - 04/2010
1	Decompression 01/2013
1	Anesthesia 01/2007
1	Hypnosis (Mesmerism) 01/2007